SCHEDULE: RA Capital Boosts VOR Biopharma Stake, Appoints New Director

RA Capital Management increased its beneficial ownership in VOR Biopharma to 14.0% through a $50 million private placement and appointed Andrew Levin to the board.

Summary

• RA Capital Management, L.P. and its affiliates (the "Reporting Persons") increased their beneficial ownership in VOR Biopharma Inc. to 14.0% of the common stock outstanding.
• This increase follows the closing of a private placement on December 18, 2025, where RA Capital Healthcare Fund, L.P. purchased 4,625,346 shares of common stock for approximately $50 million at a price of $10.81 per share.
• The total shares outstanding for VOR Biopharma Inc. increased to 38,720,196 following the private placement.
• Andrew Levin, a Partner and Managing Director of RA Capital, was appointed to VOR Biopharma's Board of Directors on December 18, 2025, replacing Sarah Reed, who resigned on December 17, 2025.
• The Reporting Persons also hold warrants exercisable for up to 11,056,072 shares, subject to beneficial ownership blockers preventing ownership exceeding 9.99% upon exercise.

Sentiment

Score: 7

Explanation: The filing indicates a significant capital injection and increased institutional investor confidence, which are positive. However, the dilution from the private placement and potential future selling pressure from registered shares introduce some caution.

Positives

• Significant investment by a major healthcare-focused institutional investor (RA Capital) demonstrates confidence in VOR Biopharma's future.
• The private placement provides VOR Biopharma with approximately $50 million in new capital from RA Capital, strengthening its financial position.
• Appointment of Andrew Levin, a Partner and Managing Director of RA Capital, to the board enhances strategic alignment and oversight.

Negatives

• The private placement resulted in dilution for existing shareholders, as 13,876,032 new shares were issued.
• The issuance of new shares at $10.81 per share could be perceived as a discount depending on the market price at the time of the agreement.
• The existence of a registration rights agreement means the newly issued shares may be resold into the market, potentially creating selling pressure.

Risks

• Beneficial Ownership Blockers prevent RA Capital from exercising all its warrants if it would result in ownership exceeding 9.99%, limiting their ability to fully convert their potential stake.
• Failure by VOR Biopharma to meet filing or effectiveness deadlines for the registration statement covering the PIPE shares could result in liquidated damages payable to investors.
• The potential resale of 13,876,032 PIPE shares by investors could increase market supply and put downward pressure on the stock price.

Future Outlook

The filing indicates VOR Biopharma Inc. plans to file a registration statement within 45 days of December 18, 2025, to allow for the resale of the shares issued in the private placement, with a target effectiveness within 75 days of the initial filing.

Industry Context

This filing reflects a common strategy in the biopharmaceutical industry where institutional investors like RA Capital provide capital through private placements, often accompanied by board representation, to support the development of promising companies. Such investments signal investor confidence and can provide crucial funding for R&D and clinical trials, which are capital-intensive in this sector.

Management Changes

Corporate Governance

Related Party Transactions

• RA Capital Healthcare Fund, L.P., an affiliate of RA Capital Management, L.P. (which has a representative on the board), purchased 4,625,346 shares of common stock for approximately $50 million in the December 2025 Private Placement.
• The Issuer entered into a Registration Rights Agreement with the December 2025 PIPE Investors, including RA Capital Healthcare Fund, L.P., to register the resale of the purchased shares.

Stakeholder Impact

• Shareholders: Experience dilution from the issuance of new shares in the private placement. May benefit from increased capital for company operations and enhanced institutional investor confidence. Potential for future selling pressure from registered shares.
• Company: Receives significant capital infusion (approximately $150 million total from the PIPE, with $50 million from RA Capital) to fund operations and strategic initiatives. Gains strategic guidance from a new board member with deep industry expertise.

Next Steps

• VOR Biopharma Inc. to file a registration statement covering the resale of the December 2025 PIPE Shares within 45 days of December 18, 2025.
• VOR Biopharma Inc. to use reasonable best efforts to cause the registration statement to be declared effective within 75 days of its initial filing.
• Andrew Levin's stock options will continue to vest in 36 monthly installments from December 18, 2025.

Key Dates

Recommendation

While the significant capital raise and increased institutional backing from RA Capital are positive signals, the immediate dilution from the private placement and the potential for future selling pressure from the registered shares warrant a 'hold' recommendation. Investors should monitor the company's use of the new capital and its operational progress, especially given the existing beneficial ownership blockers on RA Capital's warrants, before considering further investment.

Keywords

VOR Biopharma, RA Capital, Private Placement, PIPE, Schedule 13D, Biopharma Investment, Board Appointment, Equity Financing, Warrants, Shareholder Stake